Vicki Sato Biography and Net Worth

Director of Vir Biotechnology

Vicki Sato, Ph.D., has served as Chairman of our board of directors since December 2016. She was a professor of management practice at Harvard Business School from September 2006 to July 2017 and was a professor in the Department of Molecular and Cell Biology at Harvard University from July 2005 until October 2015. Previously, she served as President of Vertex Pharmaceuticals, Inc., or Vertex, a publicly-traded biotechnology company, which she joined in 1992. Prior to becoming President of Vertex, she was the Chief Scientific Officer and Senior Vice President of Research and Development. Prior to joining Vertex, Dr. Sato served as Vice President of Research at Biogen Inc. Dr. Sato is a member of the board of directors of the following public companies: Akouos, Allogene Therapeutics, and Denali Therapeutics, Inc. Dr. Sato received her A.B. in Biology from Radcliffe College and her A.M. and Ph.D. in Biology from Harvard University. She conducted her postdoctoral work at both the University of California, Berkeley and Stanford Medical Center.

What is Vicki L. Sato's net worth?: The estimated net worth of Vicki L. Sato is at least $815,151.04 as of November 7th, 2024. Dr. Sato owns 111,056 shares of Vir Biotechnology stock worth more than $815,151 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Sato may own. Learn More about Vicki L. Sato's net worth.
How do I contact Vicki L. Sato?: The corporate mailing address for Dr. Sato and other Vir Biotechnology executives is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. Vir Biotechnology can also be reached via phone at 415-906-4324 and via email at [email protected]. Learn More on Vicki L. Sato's contact information.
Has Vicki L. Sato been buying or selling shares of Vir Biotechnology?: Vicki L. Sato has not been actively trading shares of Vir Biotechnology over the course of the past ninety days. Most recently, Vicki L. Sato sold 18,000 shares of the business's stock in a transaction on Friday, June 30th. The shares were sold at an average price of $24.66, for a transaction totalling $443,880.00. Following the completion of the sale, the director now directly owns 1,315,351 shares of the company's stock, valued at $32,436,555.66. Learn More on Vicki L. Sato's trading history.
Who are Vir Biotechnology's active insiders?: Vir Biotechnology's insider roster includes Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.
Are insiders buying or selling shares of Vir Biotechnology?: In the last twelve months, insiders at the sold shares 14 times. They sold a total of 172,847 shares worth more than $1,697,678.88. The most recent insider tranaction occured on December, 2nd when EVP Verneuil Vanina De sold 76 shares worth more than $624.72. Insiders at Vir Biotechnology own 15.6% of the company. Learn More about insider trades at Vir Biotechnology.
Information on this page was last updated on 12/2/2024.

Vicki L. Sato Insider Trading History at Vir Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/30/2023	Sell	18,000	$24.66	$443,880.00	1,315,351
3/8/2023	Sell	17,935	$22.59	$405,151.65	1,327,324
2/8/2023	Sell	17,915	$28.38	$508,427.70	1,345,259
1/9/2023	Sell	17,915	$25.83	$462,744.45	1,363,174
11/8/2022	Sell	17,915	$27.38	$490,512.70	1,399,004
10/10/2022	Sell	17,915	$20.67	$370,303.05	1,416,919
9/8/2022	Sell	17,915	$21.90	$392,338.50	1,434,834
7/8/2022	Sell	17,915	$29.06	$520,609.90	1,470,664
6/8/2022	Sell	17,915	$25.84	$462,923.60	1,488,579
5/9/2022	Sell	14,541	$20.62	$299,835.42	1,503,463
4/28/2022	Sell	17,915	$20.90	$374,423.50	1,518,004
1/18/2022	Sell	15,173	$37.39	$567,318.47
12/20/2021	Sell	15,174	$54.53	$827,438.22
11/26/2021	Sell	15,174	$36.80	$558,403.20
10/19/2021	Sell	15,174	$39.56	$600,283.44
9/17/2021	Sell	15,174	$52.48	$796,331.52
8/19/2021	Sell	15,174	$45.05	$683,588.70	1,620,833
7/19/2021	Sell	15,174	$37.20	$564,472.80	1,633,325
6/21/2021	Sell	15,174	$46.17	$700,583.58	1,645,429
5/19/2021	Sell	15,174	$43.80	$664,621.20	1,660,782

Vicki L. Sato Buying and Selling Activity at Vir Biotechnology

Vir Biotechnology Company Overview

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Today's Range

Now: $7.34

$7.23

$7.56

50 Day Range

MA: $8.02

$6.74

$10.17

2 Week Range

Now: $7.34

$6.56

$13.09

Volume

3,745,310 shs

Average Volume

1,084,083 shs

Market Capitalization

$1.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.